🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

84 results for “Alnylam Netherlands B.V.” Clear

  1. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  2. VIR-2218

    Alnylam Netherlands B.V.

    Chronic Hepatitis B

    phase 2 small molecule completed

    2 trials

  3. Zilebesiran

    Alnylam Netherlands B.V.

    High Cardiovascular Risk

    phase 2 small molecule completed

    1 trial

  4. Zilebesiran

    Alnylam Netherlands B.V.

    Mild to Moderate Hypertension

    phase 2 small molecule completed

    1 trial

  5. cemdisiran

    Alnylam Netherlands B.V.

    Atypical Hemolytic Uremic Syndrome

    phase 2 small molecule terminated

    2 trials

  6. phosphate-buffered saline for SC administration

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia (HHT)

    phase 2 small molecule active

    1 trial

  7. A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  8. A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  9. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Alnylam Netherlands B.V.

    Advanced or Metastatic Hepatocellular Carcinoma

    phase 1 other active

    1 trial

  10. A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease

    Alnylam Netherlands B.V.

    Huntington’s disease

    phase 1 other active

    1 trial

  11. ALN-4285

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  12. ALN-4915

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  13. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  14. ALN-AAT

    Alnylam Netherlands B.V.

    Antitrypsin Deficiency Liver Disease

    phase 1 small molecule terminated

    1 trial

  15. ALN-AGT01

    Alnylam Netherlands B.V.

    Hypertension

    phase 1 small molecule completed

    1 trial

  16. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  18. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  19. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  20. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  21. ALN-HTT02

    Alnylam Netherlands B.V.

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  22. ALN-PCS02

    Alnylam Netherlands B.V.

    Elevated LDL-Cholesterol (LDL-C)

    phase 1 small molecule completed

    1 trial

  23. ALN-PCSSC

    Alnylam Netherlands B.V.

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  24. ALN-TTR01

    Alnylam Netherlands B.V.

    Transthyretin Mediated Amyloidosis (ATTR)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources